Brief: Theratechnologies To Develop Tesamorelin For The Treatment Of NASH In The General Population
10/09/2020 12:49
Sept 10 (Reuters) - Theratechnologies Inc TH.TO :
* THERATECHNOLOGIES TO DEVELOP TESAMORELIN FOR THE TREATMENT
OF
NASH IN THE GENERAL POPULATION
* THERATECHNOLOGIES INC - PHASE 3 PROTOCOL TO BE FILED IN Q4
2020;
TRIAL EXPECTED TO BEGIN EARLY 2021
* THERATECHNOLOGIES INC - CLINICAL STUDY TO INCLUDE HIV
COHORT
Source text for Eikon: ID:nGNX8H59DB
Further company coverage: TH.TO
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Theratechnologies
See all newsBrief: Theratechnologies Receives Final Court Approval On To Be Acquired By Future Pak
Brief: Theratechnologies Inc - Iss And Glass Lewis Recommend Voting 'For' Future Pak Arrangement
Canadian drugmaker Theratechnologies beats Q2 revenue estimates on strong demand
Brief: Theratechnologies Enters Into Definitive Agreement To Be Acquired By Cb Biotechnology, An Affiliate Of Future Pak
Brief: Theratechnologies Inc Decided To Further Evaluate Potential Sale Of Company Through An Open And Non-Exclusive Process